• English
  • 简体中文
Login Register
Current Location: Home > Drug Registration and Acceptance subscription Help
-
-
-
Visualized Analysis Export Evaluation Conclusion Evaluation Progress
Acceptance No. Drug Name Active Ingredient Dosage Form Classification Submission Acceptance Date Manufacturers Manufacturers Review Status Status Date View
JYSB2000599 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-12-03 阿斯利康投资(中国)有限公司 Astrazeneca Investment (China) Co Ltd;Catalent Indiana LLC;Astrazeneca Uk Ltd Approval Completed-Pending Certificated 2021-08-20 view
JXSS2000030 度伐利尤单抗注射液 durvalumab Injection Biological Products(3.1) Import Drug Application 2020-07-24 阿斯利康投资(中国)有限公司 Astrazeneca Investment (China) Co Ltd;Catalent Indiana LLC;Astrazeneca Uk Ltd Certificate Issued 2021-07-15 view
JXSS2000029 度伐利尤单抗注射液 durvalumab Injection Biological Products(3.1) Import Drug Application 2020-07-24 阿斯利康投资(中国)有限公司 Astrazeneca Investment (China) Co Ltd;Catalent Indiana LLC;Astrazeneca Uk Ltd Certificate Issued 2021-07-15 view
JYSB2000600 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-12-03 Catalent Indiana LLC;Astrazeneca Uk Ltd Certificate Issued 2021-03-15 view
JXSB2100011 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2021-02-06 Medimmune LLC;Catalent Indiana LLC In Review 2021-02-05 view
JYSB2100016 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2021-01-12 Catalent Indiana LLC;Astrazeneca Uk Ltd Filed 2021-01-22 view
JYSB2100015 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2021-01-12 Catalent Indiana LLC;Astrazeneca Uk Ltd Filed 2021-01-22 view
JXSB2100004 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2021-01-08 Medimmune LLC;Catalent Indiana LLC In Review 2021-01-07 view
JXSB2000041 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-12-03 Medimmune LLC;Catalent Indiana LLC In Review 2020-12-03 view
JXSB2000022 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-09-29 Medimmune LLC;Catalent Indiana LLC In Review 2020-09-28 view
JXSB2000012 度伐利尤单抗注射液 durvalumab Injection Biological Products(2.2) Supplementary Application 2020-09-10 Medimmune LLC;Catalent Indiana LLC In Review 2020-09-09 view
JXSB2000009 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-08-21 Medimmune LLC;Catalent Indiana LLC In Review 2020-08-19 view
JYSB2000358 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-08-04 Catalent Indiana LLC;Astrazeneca Uk Ltd Filed 2020-08-17 view
JYSB2000359 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-08-04 Catalent Indiana LLC;Astrazeneca Uk Ltd Filed 2020-08-17 view
JYSB2000145 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-05-01 Catalent Indiana LLC;Astrazeneca Uk Ltd Certificate Issued 2020-07-16 view
JYSB2000146 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-05-01 Catalent Indiana LLC;Astrazeneca Uk Ltd Certificate Issued 2020-07-16 view
JYSB2000113 度伐利尤单抗注射液 durvalumab Injection Biological Products Supplementary Application 2020-04-09 Medimmune LLC;Cook Pharmica LLC In Review 2020-04-08 view
JXSL2300031 度伐利尤单抗注射液 durvalumab Injection Biological Products(2.2) Import Drug Application 2023-02-02 Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd view
JXSS2400096 度伐利尤单抗注射液 durvalumab Injection Biological Products(3.1) Import Drug Application 2024-10-18 Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd view
JXSS2500013 度伐利尤单抗注射液 durvalumab Injection Biological Products(3.1) Import Drug Application 2025-02-21 AstraZeneca AB;Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd view